Navigation Links
Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b

Helix BioPharma Corp.

AURORA, ON, March 30, 2007 /PRNewswire-FirstCall/ - Helix today announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV) induced low-grade cervical lesions.

The study showed a clinically efficacious response to treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant local intolerance or drug-related serious adverse event observations.

"Treated patients responded well, both in terms of efficacy and safety to this new investigational therapeutic," said Prof. Dr. med. Achim Schneider M.P.H., a world expert in the field of cervical cancer and Director of the Department of Gynaecology at the Charite University Hospital in Berlin. "Helix's product shows real promise as a practical and effective pharmaceutical means of preventing cervical cancer development in women presenting with HPV-induced cervical lesions", continued Prof. Schneider.

About the Clinical Study

A total of 41 women with cytologically confirmed, HPV-induced low-grade squamous intraepithelial lesions (LSIL) of the cervix were studied across four sites in Germany. Twenty women received Topical Interferon Alpha-2b, self-administered intravaginally three times per week for a period of 6 weeks with a follow-up evaluation at 12 weeks, compared with 21 separately studied women who received no treatment whatsoever over the same study period.

The primary endpoint and main outcome for both groups was the Pap-response rate defined as the proportion of patients with resolution of their abnormal Pap smear LSIL cytology to normal during the 12 week study duration. Pap smear normalization was considered to occur if the patient's Pap smear improved to group II or better from any of Pap smear groups IIW through IIID as per the common European stan
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
8. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
9. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
10. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:10/6/2008)...oncept of Other Product - Company,s Bioabsorbable ... HONG KONG, Oct. 6 /- Data from mult...ing stent, OrbusNeich,s Genous Bio-engineered R,st...ter Cardiovascular,Therapeutics symposium, TCT 200...Ph.D., of the Academic Medical Center in,Amsterdam...
(Date:10/3/2008)...IK, Iceland, Oct. 3 /- deCO...iling of an investigational new drug,(IND) applica... modulator,of phosphodiesterase 4 (PDE4), with the...nd is being developed as a new and potentially saf...nd cognitive deficits associated,with Alzheimer,s ...
(Date:10/2/2008)...October 2 /- Pharmaleads has obtained...horization to perform a single,ascending dose Phas...eatment of neuropathic pain., Neuropathic pain is...,prevalence in the world,s population of up to 6%,...auses such as shingles, herpes, diabetes,antivira...
(Date:10/2/2008)... England, October 2 /- Circassia Ltd,...the fields of allergy and critical,care, today ann...udy of its,ToleroMune(R) technology in the field o...s achieved in an earlier phase II study, which dem...oleroMune approach to allergy,desensitization., I...
Breaking Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 1Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 3New study finds biodiversity conservation secures ecosystem services for people 1471 1New study finds biodiversity conservation secures ecosystem services for people 1471 2Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 1Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 2CME LLC Restructures Announces Its New Executive Management Team 2074 1CME LLC Restructures Announces Its New Executive Management Team 2074 2
(Date:10/6/2008)... LearnCDHC, a Web-based resource de...r-directed healthcare (CDHC) options including Hea...Accounts (HRAs) and Flexible Spending Accounts (FS...ia, to offer enterprise level services in concert ...dsize business model. , ...
(Date:10/6/2008)...ober 10th, military personnel and their family mem...rson self-assessments, BOSTON, Oct. 6 /PRNewswire...es to Service members and their families that are ...e not. In some instances matters get,worse and one... such times,it is wise to check things out to see ...
(Date:10/6/2008)... results from two Phase 3 studies presented at the...tific Meeting (ACG) in Orlando, Fla., demonstrated...han lansoprazole among patients with more severe g...nes dexlansoprazole with a Dual Delayed Release (D...releases of drug for extended duration of acid sup...
(Date:10/6/2008)...RSEY, Oct. 6 /PRNewswire/ -- The organizers of Inf...nference on Global Sourcing for the,Pharmaceutical... the,Princeton Marriott in New Jersey USA., The c... CEO of the,Global Sourcing Council, and boasts an...ding the likes of Johnson & Johnson, Bristol Myers...
Breaking Medicine News(10 mins):Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2
...n tried to quell fears of a pandemic by saying the...is country // , is now under control. "The situa...onitor it closely," Erdogan newsmen with visiting ...i. "So for the time being any danger is out of the...
...tralia. An elderly woman died on 8th January at th...om advance stage of cancer // . She was tested pos...nfusion among the health care officials in Austral...was admitted in the Adelaide hospital and for canc...
... leading cancers in the world today. The problem i... thus the treatment, which includes radiation and ...f tissue leading to disfigurement. Now two Virgin...th the American Dental Association (ADA) to build ...
...Arizona State University have successfully produce...hers were able to produce vaccines from bioenginee...t guinea pigs which were exposed to pneumonic plag...ical trial of the new vaccine in human to study th...
Other Medicine News:Health News:Turkish PM says bird flu under control 2Health News:Tobacco plant based Vaccine against Plague 2
Suture retriever forceps
Knot pusher/suture retriever
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture.
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand
Medicine Products: